Biotechnology
AstraZeneca Unveils In-House ADCs, Rivaling AbbVie and Pfizer’s Cancer Therapies
AstraZeneca, Daiichi Sankyo, Antibody-Drug Conjugates (ADCs), Cancer Therapies, AbbVie, Pfizer, Oncology, Biotechnology
Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul
Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.
BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties
BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain
Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis
Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration
Unveiling the Future of Biotech: Top 11 Startups to Watch in 2024
Biotech startups, Top biotech companies, Biotechnology industry, Emerging biotech trends, Biotech innovation, Biotech awards
Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases
Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.
Navigating Challenges and Opportunities in the 2024 Life Sciences Industry Outlook
Life Sciences Industry, 2024 Outlook, Biotechnology, Medical Devices, Artificial Intelligence, Drug Pricing, Regulatory Changes, Supply Chain Security, Talent Shortage
Ultimovacs Cancer Vaccine Faces Significant Challenges After Third Consecutive Failure
Ultimovacs, cancer vaccine, phase 2 trial, clinical failure, financial struggles, biotechnology
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
WuXi AppTec Faces Revenue Decline Amid Looming BIOSECURE Act Threat
WuXi AppTec, BIOSECURE Act, Revenue Decline, Biotechnology, US-China Relations